Summary Zinc in various therapeutic doses was used on patients suffering from oral mucositis during cancer treatment. A meta-analysis was conducted to probe the role of oral zinc as a possible treatment option for oral mucositis. A literature search was done using PubMed, EBSCO, Cochrane, MedLine, ScienceDirect, ResearchGate and Google Scholar with key words. The analysis was directed to recognize and identify the use of zinc supplementations at a confidence interval (CI) 95% with p value significance taken as ,0.05. A total number of 21,428 articles was retrieved. After thorough screening and assessment of the eligibility criteria, 10 articles were included in qualitative and quantitative analysis in the study. The 10 articles constituted a total sample size of 299 in the case group and 294 in the control group. Oral zinc doses used were 25 mg, 30 mg, 50 mg and 220 mg capsules and mouthwash of 0.2% zinc, as well as 0.5 g of granules dissolved in 5% sodium alginate solution. Two studies showed no significance, with the overall effect 1.61. Eight studies favored zinc over a placebo with an overall effect size of 20.89 at 95% CI of 21.08 and 20.70 which was statistically significant (Z59.27, p,0.00001). This analysis suggests that zinc usage has shown significant reduction in the severity of oral mucositis but not prevention. The onset of the reaction was delayed and hastened healing. Pharyngeal mucositis, pain and quality of life of the individuals received no effect from zinc therapy.
Oral mucositis is a term applied to erythematous and ulcerative lesions of the oral mucosa (1) . Mucosal damage is an unavoidable and critical issue with considerable side effects related to dose and duration, occurring in oral, pharyngeal, laryngeal, oesophageal and gastrointestinal regions in patients with head and neck cancer on chemotherapy and/or radiotherapy (1) (2) (3) (4) (5) . Approximately 60% of patients receiving radiotherapy develop oral mucositis and the incidence may increase up to 90% with concurrent chemotherapy (6) . Symptoms such as a burning sensation and pain are due to loss and thinning of the mucosal epithelial barrier during the treatment, transforming into a painful, debilitating condition, depriving the patient of nutrition and oral care, and potentially acting as a source of infection (2, 5, 7, 8) .
Severe mucositis may limit the treatment schedule leading to increased hospitalization, thereby increasing the economic burden (1, 2) . Many treatment modalities have been prescribed to prevent the occurrence or to reduce the intensity of oral mucositis, such as antibiotics, anti-inflammatory agents, honey, sucralfate, amifostine, and vitamins A and E, either prophylactically or after the onset (2) . According to recent MASCC/ISOO clinical guidelines, the various treatment modalities include oral cryotherapy, KGF-1 (human keratinocyte growth factor), and low-level laser therapy, which may aid in prevention of oral mucositis. Two percent morphine mouthwash, transdermal fentanyl patches and 0.5% doxepin mouthwash were also recommended for alleviation of pain (9) (10) (11) .
Zinc is a ecessary trace element and micronutrient with diverse roles in physiologic processes such as in growth and development, in maintenance of the immune system and in tissue repair. It is an essential component needed for regulation of lipid, protein and nucleic acid metabolism and gene transcription (12, 13) . Rapid cell division in wounds is associated with increased demand of zinc, emphasizing its role in wound healing. It has an antioxidant property, which stabilizes E-mail: nallanchaitanya@gmail.com membranes and prevent free radical-induced injury during inflammatory processes (14, 15) . The recommended daily allowance of zinc is 10 mg/d for children aged 1-10, 15 mg/d for adolescents and adults, and 20-25 mg/d during pregnancy and lactation. For therapeutic purpose zinc is administered orally or parenterally as zinc sulfate (22.5 mg of elemental zinc/100 mg), zinc acetate (30 mg elemental zinc/100 mg), or zinc oxide (80 mg elemental zinc/100 mg) (12) .
Zinc is known for its anti-inflammatory properties in oral mucositis developing during cancer therapy. However, its role has been implicated with considerate success in containing mucositis only in small study settings. Hence a need was felt to evaluate its role by performing a meta-analysis incorporating all the relevant studies using zinc as an agent for prevention or treatment of oral mucositis.
Materials and Methods
Search strategy. An extensive literature search was performed using databases such as PubMed, EBSCO, Cochrane, MedLine, ScienceDirect, ResearchGate and Google Scholar. The key words used for the search were Oral Mucositis, Cancer Concurrent Chemo-radiotherapy, Radiotherapy, Chemotherapy, and Zinc supplements. The search was carried out incorporating the published literature from 1981-2017 using the above MeSH (medical subject heading) terms.
Only randomized controlled trials were included in the study. Those studies incorporating zinc as the primary investigational agent for evaluating oral mucositis during cancer therapy were taken into consideration. Care was also taken to include those which compared the drug with a placebo or none. Hadorn et al.'s criteria served as a measuring tool for the quality of the searched items (16) .
Exclusion criteria followed during the search were those articles not in English, articles where only the abstract was available, case reports, cohort studies, studies involving multivitamin usage along with zinc, poorly designed studies and review articles.
Three research assistants actively contributed to the literature database search, article retrieval and analysis of the same in accordance with the protocol of the study.
Data selection, recovery and analysis. A primary researcher and three-research assistants facilitated data selection and recovery. Research assistant 1 was involved in literature associated with cancer chemotherapyinduced oral mucositis and zinc supplementation. The second research assistant analyzed research on concurrent chemo-and radiotherapy-induced oral mucositis and zinc supplementation. The third research assistant searched for exclusive radiotherapy-related articles focusing on zinc supplementation for oral mucositis. All of them reported to the primary researcher who was the final authority in study consideration during the search, if any discrepancies existed.
The articles satisfying the eligibility criteria, good design and proper conclusions pertaining to usage of zinc in oral/topical forms during cancer treatment to prevent or reduce the occurrence of mucositis were extracted and utilized for the meta-analysis. Studies pertaining to naso-pharyngeal and oro-pharyngeal carcinomas were also included. Thus, obtained data was tabulated in the Excel format with divisions of gender, diagnosis of the type of carcinoma, treatment of zinc, grading of mucositis and curative treatment offered for the cancer. Data extracted were subjected to statistical analysis using RevMan software, version 5.
The analysis was directed to recognize and identify the use of zinc supplementations in reducing oral mucositis induced by cancer chemo and/or radiotherapy. A confidence interval (CI) of 95% with p value significance taken as ,0.05 was taken as criteria for obtaining the statistical association between usage of zinc and occurrence of mucositis. Other variables like pain, quality of life, and tumor size regression were not considered, primary concentration being put on only the oral mucositis scores and severity.
Results

Primary search strategies
Zinc intervention vs controls. Overall 21,428 articles were retrieved from all the search databases. After thorough screening and assessment of the eligibility criteria, 4,483 articles out of the total number were considered. Thirteen full text articles were confirmed eligible for advanced screening. A total of 10 articles was included in qualitative and quantitative analysis in the entire study. Three articles were excluded from the study for the following reasons. A study by Sangthawan et al. was excluded as it had the primary objective evaluating the impact of zinc sulfate supplementation on the absolute numbers of circulating T lymphocytes and T lymphocyte subpopulations in cancer patients but not on oral mucositis (17) . The other two articles had assessed the efficacy of oral polaprezinc on oral mucositis during cancer chemo/radiotherapy. The compound was similar in all three studies; hence, to avoid duplication of the research, only the study by Watanabe et al. (18) was taken into consideration.
The 10 articles constituted a total sample size of 299 in the case group and 294 in the control group. All 10 articles have demonstrated that oral mucositis occurred irrespective the modality of treatment employed, such as radiotherapy, chemo-radiotherapy or chemotherapy during cancer treatment. Zinc supplementations had been the modality of treatment for oral mucositis in the case group and a placebo drug in the control group. The correlation of zinc treatment and severity of oral mucositis was estimated at a 95% confidence interval (CI) ( Table 1) . PRISMA flowchart is shown in Fig. 1 .
Gender could not be concluded to have played a role in most of the studies due to the unequal percentage of gender participation in many studies. Males constituted a significant number of subjects undergoing treatment for cancers. Most of the carcinomas treated were of the nasopharyngeal variety followed by the oral varieties, mainly the carcinoma involving buccal mucosa and the tongue. The radiotherapy dose was maintained between 60 and 70 Gy with the naso pharyngeal variety receiving the highest dosage. The chemotherapy was employed as a once-weekly intravenous dose for a period ranging from 4-6 wk. Two out of three chemotherapy studies concentrated on acute leukemia and one of the studies was on nasopharyngeal carcinomas only. Only one article had employed only radiotherapy as a treatment for the patients with head and neck cancers.
Fixed and random effects were demonstrated using square and shrinkage and the likelihood of being the causation of the effect with fixed squares. The studies included were complete with respect to assessment of mucositis and score grading in all the participants within the sample. The sample, which was obtained with scoring of all the studies, was large, leading to usage of the fixed effect rather than the random effect, which depends on a small sample size. Commencement of zinc supplementation also varied among the studies. Five of the studies had initiated zinc therapy from the first day to the last day of cancer treatment (1, 5, 7, 9, 18) . Three studies had employed different time intervals of zinc treatment ranging from 10 d prior to cancer therapy till 6 wk after cessation of the therapy (2-4). Two studies (6, 8) , did not have any data.
Despite the results, methodology employed for estimating the zinc efficacy over oral mucositis occurrence differed in most of the studies. The form of oral supplementations used was oral zinc, which was prescribed as 25 mg, 30 mg, 50 mg and 220 mg capsules, mouthwash of 0.2% zinc, and 0.5 g of granules dissolved in 5% sodium alginate solution. Two studies showed no significant effect of zinc supplementation; the overall effect was 1.61, which was insignificant statistically. The rest of the studies favored zinc treatment in oral mucositis and zinc helped in the reduction of mean burning sensation much better than the placebo with an overall effect size of 20.89 at a 95% CI of 21.08 and 20.70, respectively. It was statistically significant (Z59.27, p,0.00001) ( Table 1) .
Grading of oral mucositis. The present study analyzed the effect of drug intervention on oral mucositis during cancer treatment by utilizing the scales meant for measuring the grades of mucositis at regular intervals. Measurement was included as one of the criteria to assess the performance of the interventions in both the case and control groups.
The various scales of oral mucositis used were Radiation oncology toxicity grading (RTOG, 5 studies), Common Terminology Criteria for Adverse Events (CTCAE, 1 study), WHO score (2 studies), Oral mucositis assessment scale (OMAS score, 1 study) and Spijkervet scoring system (1 study). In all the studies, the fixed effects model of meta-analysis was employed. The relative risk for oral mucositis grading using RTOG scales in the Gorgu et al. (8) (Fig. 2) . The study by Mehdipour et al. showed the highest weightage in this category, which used the Spijkervet scoring system (4). Overall, the studies which employed RTOG scoring showed the highest weightage. The heterogeneity was maintained at 33.55 and degree of freedom at 6 for all the studies grouped together. The statistical result showed a significant percentage of results pointing towards oral mucositis scores improving with zinc usage when compared to a placebo (Fig. 3) . A small variation in the Gorgu et al. study, which used singlearm intervention, could be attributed to scoring or methodological parameters (8) .
The funnel plot of the studies demonstrated that they were falling within the parameters of the triangle with equal and uniformed sides of the triangle. Studies employing the OMAS score and studies which employed RTOG grading dispersed out of the funnel chart, probably indicating a publication bias of the studies. It was noteworthy to mention that 8 of the studies fell under funnel chart (Fig. 4) .
Discussion
Oral mucositis is a complicated adverse reaction during cancer treatment invariably affecting the outcome of the therapy. Radiotherapy-treated individuals have about 100% occurrence of oral mucositis compared to those with chemotherapy alone, which accounts for 40% (19) . These unavoidable sequalae were the subject of various treatment strategies which yielded partial success. The present study included 10 articles, in which out of 299 case group samples, zinc helped in the reduction of mean burning sensation much better than a placebo. The overall effect size was 20.89 with a 95% CI of 21.08 and 20.70, respectively, among the 8 studies analyzed statistically. The test for subgroup differences (I 2 ) was 79.5% and 63%. There was much heterogeneity in the studies carried out, attributable to the methodological differences included in analysis. It was also observed that the zinc therapy had less effect on patients who suffered from naso-pharyngeal carcinomas than oral carcinomas, in particular. However, few studies showed less significant reduction of oral mucositis; that is, zinc was only 49% more potent in decreasing mucositis when compared to other treatments. But the heterogeneity of the studies was 76% (3, 6, 8) .
Of note, one study stated that the usage of zinc supplementation dosage should be increased above the initial dose during the cancer radio-chemotherapy, as the therapy nears its completion. This could be attribable to depletion of serum-zinc levels in the individuals undergoing cancer treatment (3, 5, 8) .
A majority of males participated in most of the studies and the female population undergoing cancer chemoradiotherapy was considerably smaller. This aspect might not have had much influence over the results of the study analysis.
Oral mucositis grading and scoring was carried out with the help of different scales by the studies included in the analysis. The RTOG scale was commonly employed followed by WHO grading. The scales or grading employed had no effect on the analysis of the studies comparing zinc and a placebo.
All the formulations of zinc given orally performed more or less the same way. The significant changes were observed in week 2 and week 3 in most of the zinc intervention groups in all the mentioned studies during the analysis.
Healing was reported to improve faster in the zinc supplementation groups than the placebo Groups (3). Nevertheless, it was hypothesized that the zinc supplementation could be continued for a period of 2 wk post radiotherapy or chemotherapy for a better outcome of the treatment and also better effect of the zinc over the period of time (3, 5, 7) .
The incidence of xerostomia and pain decreased in zinc supplementation group more than in the placebo group in one of the studies (7, 17) . However, the quality of life did not undergo a significant change to that of the controls with the usage of zinc. In contrast, the study by Watanabe et al., which used a drug called polaprezinc compound, showed significant improvement in quality of life, prompting further investigations into this aspect. The parameters such as the age, duration of therapy, gender and weight have not been shown to have any influence on the results in the present analysis, as most of the studies had reported no significant change in these parameters (18) .
Dermatitis showed more improvement in the zinc group than the placebo in certain studies (1, 5) . Conversely, pharyngeal mucositis did not show improvement with zinc supplementation (1, 8) . Notably, a study by Sangthawan et al. showed that the zinc had no effect on the number or the survival of circulating T lymphocytes (17) . Areca nut chewing with increased copper content may have had a significant role when such lesions were treated with zinc therapy, because of potential interaction of zinc with mucosal metaallothionein, interfering with copper metabolism (6) . It was also demonstrable that zinc acted better on sloe treatment groups such as those with only radiotherapy or chemotherapy but performed less well in concurrent chemo-radiotherapy treatment individuals.
Conclusion
Overall, it could be comfortably stated that zinc administration has shown good effect on reducing the severity of oral mucositis but not its prevention. It also delayed the onset of the reaction and allowed quick healing in post cancer therapy. No effect was shown on pharyngeal mucositis, pain or quality of life in individuals on zinc therapy. Similarly, those patients with low serum zinc levels at pre radio/chemotherapy showed increased severity of mucositis. Hence, dosing with zinc prior to cancer treatment initiation would be beneficial to contain the severity of the oral mucositis.
Limitations
Pretreatment zinc serum levels were not assessed in most of the studies, probably altering the way dosage of zinc would be determined. Additionally, post-treatment zinc supplementation was provided in only limited studies; therefore, the effect of zinc on healing and follow up of lesions post cancer treatment was variable, which might not yield a definitive conclusion on continuing zinc post cancer therapy. Uniformity of grading or scales used for the assessment of mucositis would have resulted in a better and definitive outcome in the study.
